Severe early-onset intrauterine growth restriction (IUGR) in a woman with Asherman's syndrome

Yasmin, H; Adeghe, J. H.

doi:10.1080/01443610410001660968

Cited by 7 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Known obstetric complications of patients with AS after surgical treatment include preterm birth [9,13], low birth weight [9,13], intrauterine fetal demise [13], IUGR [10,13], and hemorrhage caused by MAPs [11,13]. Our study did not include any cases of intrauterine fetal demise.…”

Section: Discussionmentioning

confidence: 99%

Effects of Asherman Syndrome on Maternal and Neonatal Morbidity with Evaluation by Conception Method

Wang

Movilla

Morales

et al. 2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

Create a comprehensive summary of maternal and neonatal morbidities from patients previously treated for Asherman syndrome and evaluate for differences in perinatal outcomes based on conception method. Design: Retrospective cohort. Setting: Community teaching hospital affiliated with a large academic medical center. Patients: Total of 43 singleton births identified from 40 patients previously treated at our institution for Asherman syndrome. Interventions: Review of fertility and obstetric data to summarize the maternal and neonatal outcomes in singleton births from patients with Asherman syndrome who had been treated with hysteroscopic adhesiolysis. Measurements and Main Results: Primary outcomes of maternal morbidity (i.e., hypertensive disease, gestational diabetes, ruptured membranes, postpartum hemorrhage, morbidly adherent placenta [MAP]) and secondary outcomes of neonatal morbidity (i.e., gestational age at birth, method of delivery, weight, length, 1-and 5-minute Apgar score oxygen requirement, anatomic malformations, length of neonatal admission) were evaluated. We identified 40 patients who completed successful treatment of Asherman syndrome and went on to carry a singleton gestation within our institution: 20 (50%) with mild disease, 18 (45%) with moderate disease, and 2 (5%) with severe disease under the March classification system. In total, 43 singleton births were examined, with 27 of 43 (62.8%) conceived without in vitro fertilization (IVF) (group A: non-IVF conception) and 16 of 43 (37.2%) conceived through IVF (group B: IVF conception). The overall rate of preterm birth in Asherman pregnancies was 11.6%, with no difference between the 2 conception groups. We documented 9.3% cases with intrauterine growth restriction, with no difference based on conception groups. The rate of MAP in patients with Asherman syndrome was 14.0%, and the rate of postpartum hemorrhage was 32.6%, with no differences between the conception groups. Newborn anatomic malformations of any cause were documented in 18.6% of all singleton births, with no difference between the conception groups. Conclusion: Our series indicates a higher incidence of intrauterine growth restriction, MAP, postpartum hemorrhage, and newborn anatomic malformations in Asherman syndrome pregnancies than that reported in pregnancies within the general population. However, we found no significant differences in the maternal and neonatal outcomes of patients with Asherman syndrome who conceived with or without IVF after being treated with hysteroscopic adhesiolysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Asherman Syndrome on Maternal and Neonatal Morbidity with Evaluation by Conception Method

Wang

Movilla

Morales

et al. 2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

show abstract

“…Furthermore, the issue of pregnancy safety needs to be considered. Cases of fetal growth restriction and placenta accreta have been reported in AS patients . Many of the cell therapy trials have not addressed these concerns.…”

Section: Safety and Efficacy Considerations For Cell Therapiesmentioning

confidence: 99%

Cellular therapies for the endometrium: An update

Queckbörner

Davies

Grothusen

et al. 2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

An update on the current state of endometrial cell therapies in terms of cell types, mechanisms of action, delivery, safety, regulatory frameworks and future perspectives. This review focuses on clinical trials using angiogenesis‐promoting therapies and stromal therapies piloted in the last 10 years for alleviating Asherman's syndrome and long‐term infertility. All studies present promising preliminary results, indicating increased endometrial thickness and resumed menstruation. Further characterization of individual cell products, their mode of action and larger clinical trials will be essential to establishing cell therapy as a viable option for the treatment of infertility and fertility preservation.

show abstract

“…Several obstetric complications have been reported in women with corrected AS like miscarriages, [ 10 – 13 ] abnormal placentation, [ 14 – 19 ] cervical incompetency, [ 15 , 20 ] intrauterine growth retardation (IUGR), [ 21 ] premature birth, [ 22 – 24 ] uterine rupture, [ 25 – 27 ] and preeclampsia may also be another complication after AS.…”

Section: Introductionmentioning

confidence: 99%

The birth weight in pregnant women with Asherman syndrome compared to normal intrauterine cavity

Baradwan

Bashir³

et al. 2018

Medicine

View full text Add to dashboard Cite

Women with Asherman syndrome (AS) have damaged endometrium and reduced blood flow to the uterus and placenta which may lead to low birth weight and several obstetric complications.The objective is to determine the association between low birth weight and obstetrical complications in women with AS compared to women with normal intrauterine cavity.A retrospective case-control study was conducted in Women's Specialized Hospital, King Fahad Medical City, from December 2008 to December 2015. Pregnant women with AS undergoing hysteroscopic adhesiolysis who presented to our clinic were matched for age, parity, body mass index, methods of conception, and gestational age to pregnant women without AS based on a 1:3 ratio. The main outcome measure included birth weight and obstetrical complications.The study included 56 women with 14 cases and 42 controls. Pregnant women with AS had significantly lower birth weight (2.23 ± 0.28 kg) compared with pregnant women without AS (3.13 ± 0.383 kg) (P < .001 odds ratio [OR] 0.029, 95% confidence interval [CI] 0.006–0.148, P = .001). Complications of delivery including retained placenta, placenta previa, and fetal death were significantly higher in patients with AS compared with controls 28.6% 7.1%, and 7.1% compared to 4.8%, 0%, and 0%, respectively. This was statistically significant (P < .001).Pregnant women with AS delivered low birth weight newborns and had more obstetrical complications as compared with pregnant women with normal cavity.

show abstract

Severe early-onset intrauterine growth restriction (IUGR) in a woman with Asherman's syndrome

Cited by 7 publications

References 1 publication

Effects of Asherman Syndrome on Maternal and Neonatal Morbidity with Evaluation by Conception Method

Effects of Asherman Syndrome on Maternal and Neonatal Morbidity with Evaluation by Conception Method

Cellular therapies for the endometrium: An update

The birth weight in pregnant women with Asherman syndrome compared to normal intrauterine cavity

Contact Info

Product

Resources

About